Abstract
8035 Background: The outcome of patients (pts) with HIV-HL has improved since the introduction of highly active antiretroviral therapy (HAART). The current trial was initiated to investigate a risk adapted treatment strategy in pts with HIV-HL as established in HIV-negative pts with HL. Methods: Pts were planned to receive 2x ABVD + 30 Gy involved field (IF) radiation for early stage (ES) favourable HL (stage I/II without risk factors), 4x BEACOPP baseline + 30 Gy IF for ES unfavourable HL (extranodal involvement, large mediastinal mass, ≥ 3 lymph node areas involved), and 6-8 × BEACOPP baseline for advanced stage HL. BEACOPP should be replaced by ABVD in pts with far advanced HIV-infection. HAART was given concomitantly with chemotherapy. The primary endpoint was tolerability and treatment related mortality. Secondary endpoints include event free survival (EFS) and overall survival (OS). Results: 93 pts (7 females) were included in the trial. 18/93 pts (19%) had ES favourable HL, 13 (14%) ES unfavourable...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
